These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34365714)

  • 1. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course.
    Yalici-Armagan B; Tabak GH; Dogan-Gunaydin S; Gulseren D; Akdogan N; Atakan N
    J Cosmet Dermatol; 2021 Oct; 20(10):3098-3102. PubMed ID: 34365714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic.
    Topaloğlu Demir F; Polat Ekinci A; Aytekin S; Topkarcı Z; Aslan Kayıran M; Özkök Akbulut T; Oğuz Topal İ; Sarıkaya Solak S; Kara Polat A; Karadağ AS
    J Cosmet Dermatol; 2023 Mar; 22(3):722-731. PubMed ID: 36630728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis.
    Gisondi P; Geat D; Bellinato F; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1521-1529. PubMed ID: 35930356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
    Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
    Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis [Formula: see text].
    Ladda M; Lynde C; Fleming P
    J Cutan Med Surg; 2020; 24(6):625-632. PubMed ID: 32757760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5".
    Potestio L; Camela E; Fabbrocini G; Megna M
    J Cosmet Dermatol; 2021 Dec; 20(12):4073-4075. PubMed ID: 34708906
    [No Abstract]   [Full Text] [Related]  

  • 9. Surveillance of psoriatic patients on biologic treatment during the COVID-19 pandemic: A single-center experience.
    Polat Ekinci A; Pehlivan G; Gökalp MO
    Dermatol Ther; 2021 Jan; 34(1):e14700. PubMed ID: 33369063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: A single-center retrospective study in Japan.
    Uchida H; Kamata M; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2022 Jun; 49(6):624-628. PubMed ID: 35319126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.
    Ghoreishi Amin N; Khosravi S; Atefi N; Seirafianpour F; Farhoodi S; Goodarzi A
    Immun Inflamm Dis; 2023 Nov; 11(11):e1063. PubMed ID: 38018599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should biologics for psoriasis be interrupted in the era of COVID-19?
    Lebwohl M; Rivera-Oyola R; Murrell DF
    J Am Acad Dermatol; 2020 May; 82(5):1217-1218. PubMed ID: 32199889
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical management of psoriasis patients during the COVID-19 pandemic.
    Chat VS; Uppal SK; Kearns DG; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):1166-1167. PubMed ID: 32568009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
    Zitouni J; Bursztejn AC; Belloni Fortina A; Beauchet A; Di Lernia V; Lesiak A; Thomas J; Topkarci Z; Murashkin N; Brzezinski P; Torres T; Chiriac A; Luca C; McPherson T; Akinde M; Maruani A; Epishev R; Vidaurri de la Cruz H; Luna PC; Amy de la Bretêque M; Lasek A; Bourrat E; Bachelerie M; Mallet S; Steff M; Bellissen A; Neri I; Zafiriou E; van den Reek JMPA; Sonkoly E; Mahil SK; Smith CH; Flohr C; Bachelez H; Mahé E;
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2076-2086. PubMed ID: 35748102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and psoriasis: biologic treatment and challenges.
    Ebrahimi A; Sayad B; Rahimi Z
    J Dermatolog Treat; 2022 Mar; 33(2):699-703. PubMed ID: 32598204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.
    Mroz M; Mućka S; Miodońska M; Ziolkowska D; Hadas E; Bożek A
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577804
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul.
    Kara Polat A; Oguz Topal I; Karadag AS; Aksoy H; Koku Aksu AE; Ozkur E; Ozkok Akbulut T; Topaloglu Demir F; Engin B; Uzuncakmak TK; Kıvanc Altunay I
    Dermatol Ther; 2021 Jan; 34(1):e14691. PubMed ID: 33351215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
    Sadeghinia A; Daneshpazhooh M
    Dermatol Ther; 2021 Jan; 34(1):e14498. PubMed ID: 33141519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.
    Liu M; Wang H; Liu L; Cui S; Huo X; Xiao Z; Zhao Y; Wang B; Zhang G; Wang N
    Front Immunol; 2022; 13():1046352. PubMed ID: 36389759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
    Galluzzo M; Tofani L; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.